Innovative Molecules Announces First Patient Dosed in Phase 2a Trial of Adibelivir (IM-250), Advancing Company into Late-Stage Clinical Development

Contributed by: PR Newswire

Tags

Innovative-Molecules

More Like This

PR Newswire associated0

Innovative Molecules Announces Completion of Phase 1 Program and Advancement to Phase 2 for Oral Adibelivir

PR Newswire associated0

Innovative Molecules Completes Enrollment of Phase 1b Clinical Trial of IM-250

PR Newswire associated0

Alfasigma Secures Exclusive Rights from Innovative Molecules to Parenteral Adibelivir for Treatment of HSV Encephalitis, an Ultra-Rare Disease

Innovative Molecules Expands Virology Pipeline with Novel EBV Antiviral Program

Genethon and Hansa Biopharma announce initiation of a Phase 2 trial of imlifidase as a pre-treatment to GNT-0003 in severe Crigler-Najjar syndrome

Biotech company Eradivir is developing lead drug EV25 to treat influenza

PR Newswire associated0

IRBM Reports Breakthrough in Zika Virus Drug Discovery

ACCESSWIRE logo

NanoViricides Announces that Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun